AURA News

The IPO market remained active this past week as 14 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion. New filers continued to pour into the IPO pipeline, with eight IPOs and seven SPACs submitting initial filings. Semiconductor foundry GlobalFoundries (GFS) priced at the high end to raise $2.6 billion at a $26...read more

Aura Biosciences, a Phase 2 biotech developing virus-like drug conjugates for ocular and urologic solid tumors, raised $76 million by offering 5.4 million shares at $14, the low end of the range of $14 to $16. The company originally planned to offer 5 million shares at the same range. At pricing, Aura Biosciences commands a fully diluted market value of $428 million.  ...read more

Aura Biosciences, a Phase 2 biotech developing virus-like drug conjugates for ocular and urologic solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aura Biosciences would command a fully diluted market value of $454...read more

Updated Monday, 10/25. The IPO market continues to stay busy with 15 IPOs schedule to raise $7.2 billion in the week ahead.   Semiconductor foundry GlobalFoundries (GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty...read more